A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors

NCT05851456 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteosarcoma
Sarcoma
Sarcoma,Soft Tissue
Bone Tumor

Interventions

DRUG: Recombinant oncolytic herpes simplex virus type Ⅰ (R130)

Sponsor

Shanghai Yunying Medical Technology

Collaborators

[object Object]